NuvOx

NuvOx Pharma already is conducting pre-clinical studies of a drug for treatment of traumatic brain injury with the Navy.

Tucson-based NuvOx Pharma has been awarded a $243,000 grant to test a drug-delivery technology to help treat infections of the heart.

The grant is from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health.

It will fund studies using the company’s “micro bubble” technology to help break up substances that can form on the heart due to endocarditis, potentially making treatment with antibiotics more effective particularly in children.

NuvOx founder and CEO Dr. Evan Unger, a University of Arizona radiology and biomedical engineering professor, is co-principal investigator on the grant along with Dr. Shelby Kutty, associate professor of pediatrics and internal medicine at the University of Nebraska Medical Center.

NuvOx is in clinical testing of another nanotechnology product for brain cancer, and the U.S. Food and Drug Administration recently granted the company an investigational drug application to test one of its drug candidates for treatment of stroke.


Become a #ThisIsTucson member! Your contribution helps our team bring you stories that keep you connected to the community. Become a member today.